Challenges to chimeric antigen receptor (CAR)-T cell therapy for cancer
about
CD19 chimeric antigen receptor (CD19 CAR)-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin's LymphomasThe cnidarian origin of the proto-oncogenes NF-κB/STAT and WNT-like oncogenic pathway drives the ctenophores (Review)Epigenetic suppression of the antitumor cytotoxicity of NK cells by histone deacetylase inhibitor valproic acid.The Antitumor Efficacy of IL2/IL21-Cultured Polyfunctional Neu-Specific T Cells Is TNFα/IL17 Dependent.A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy.New approaches for the immunotherapy of acute myeloid leukemia.Chimeric antigen receptor-engineered natural killer and natural killer T cells for cancer immunotherapy.Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors.The Immune System in Cancer Pathogenesis: Potential Therapeutic Approaches.The Heat-Stable Enterotoxin Receptor, Guanylyl Cyclase C, as a Pharmacological Target in Colorectal Cancer Immunotherapy: A Bench-to-Bedside Current Report.CAR-T cell therapy in ovarian cancer: from the bench to the bedside.Accurate control of dual-receptor-engineered T cell activity through a bifunctional anti-angiogenic peptide.Overcoming Resistance of Human Non-Hodgkin's Lymphoma to CD19-CAR CTL Therapy by Celecoxib and Histone Deacetylase Inhibitors.
P2860
Q26749139-D9AE543A-8D75-42F8-8AFD-015690DA0F9BQ26799398-E2B772D3-8C34-4EF1-B76D-256201FB5D5CQ36853857-D1700872-3C34-42DA-BE0D-C26CCEC23B94Q36863278-757D9002-E52E-4608-9B8F-B4356CD2F182Q37555940-FF5D8C14-7B76-4701-B49A-E430F246176EQ38482206-9F3FD0E2-24C0-4C01-9B20-96630D173D96Q38666579-316E0979-0B24-4A53-9C42-62A7AB2A4D4DQ38742968-D6C1A88F-2B6E-4C2D-B2BF-764F55A236CDQ39100049-C5A99B7B-61F0-4EDF-A8AC-2C5F827B42C5Q41669233-779DE823-B305-40B8-B9FA-76C23E4996A1Q42362802-87F0D4FA-E701-4B54-8D17-2CCA2CF9D9F2Q52646462-EBAC4686-79BB-4090-8471-BE31E21748BBQ55515652-CB286B4A-8034-4CD2-A988-E87BEC712B27
P2860
Challenges to chimeric antigen receptor (CAR)-T cell therapy for cancer
description
2014 nî lūn-bûn
@nan
2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Challenges to chimeric antigen receptor (CAR)-T cell therapy for cancer
@ast
Challenges to chimeric antigen receptor (CAR)-T cell therapy for cancer
@en
Challenges to chimeric antigen receptor (CAR)-T cell therapy for cancer
@nl
type
label
Challenges to chimeric antigen receptor (CAR)-T cell therapy for cancer
@ast
Challenges to chimeric antigen receptor (CAR)-T cell therapy for cancer
@en
Challenges to chimeric antigen receptor (CAR)-T cell therapy for cancer
@nl
prefLabel
Challenges to chimeric antigen receptor (CAR)-T cell therapy for cancer
@ast
Challenges to chimeric antigen receptor (CAR)-T cell therapy for cancer
@en
Challenges to chimeric antigen receptor (CAR)-T cell therapy for cancer
@nl
P1433
P1476
Challenges to chimeric antigen receptor (CAR)-T cell therapy for cancer
@en
P2093
Adam E Snook
P304
P407
P577
2014-11-01T00:00:00Z